COVID-19 and herpes zoster: a call to action

Noushad, Mohammed; Nassani, Mohammad Zakaria; Samran, Abdulaziz; Dimashkieh, Mohiddin R.; Al-Awar, Mohammed Sadeg

doi:10.3389/fpubh.2023.1200353

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While shingles is not life-threatening, it can be extremely painful. Getting vaccinated can reduce the risk of developing shingles [132]. In a preclinical study, Ulaszeska et al developed a novel herpes-zoster vaccine utilizing the ChAdOx1 vector and evaluated the cellular and humoral immunogenicity of ChAdOx1-expressing VZV glycoprotein E (gE) in mice, compared with the licensed live HZ vaccine and recombinant HZ vaccine in a variety of dosing regimens.…”

Section: Flu (Influenza)mentioning

confidence: 99%

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines

Trivedi,

Byrne,

Corti

2023

Viruses

View full text Add to dashboard Cite

Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative–oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.

show abstract

Section: Flu (Influenza)mentioning

confidence: 99%

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines

Trivedi,

Byrne,

Corti

2023

Viruses

View full text Add to dashboard Cite

show abstract

“…These investigations have been performed at the national or multicountry level, including broad samples of healthy individuals who received an initial two-dose schedule [ 13 – 17 ]. The evidence produced remains conflicting, and the question of whether the risk of HZ is increased in recipients of COVID-19 vaccination is still controversial [ 18 ]. Moreover, none of the available studies relied on a prospective investigation or evaluated the effects of additional mitigation strategies, including booster immunizations.…”

Section: Introductionmentioning

confidence: 99%

Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study

Nelli,

Fabbri,

Virtuoso

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Several concerns have been raised about a causal relationship between COVID-19 mRNA-based vaccines and the development of herpes zoster (HZ). We performed a prospective analysis of the Vax-On-Third-Profile study to investigate the incidence of HZ after the third dose of mRNA-BNT162b2 (tozinameran) and its correlation with immune responses. Patients who had received a booster dose and had been actively treated for at least 8 weeks were eligible. Serologic assessment was performed before the third dose of tozinameran (timepoint-1) and 4 weeks later (timepoint-2). We also assessed the incidence of SARS-CoV-2 breakthrough infections at predefined time points. The current analysis included 310 patients, of whom 109 (35.2%) and 111 (35.8%) were being treated with targeted therapies and cytotoxic chemotherapy, respectively. All participants received a third dose of tozinameran between September 26 and October 30, 2021. After a mean follow-up of 17.3 (IQR 15.1–18.4) months, HZ occurred in 8 recipients, for a cumulative incidence of 2.6%, and an incidence rate of 0.310 per person-year (95% CI 0.267–0.333). All HZ cases occurred within 30 days of booster dosing (range 5–29 days), with a median time to onset of 15 (IQR 9–22) days. Among the 7 patients (2.2%) who also contracted a SARS-CoV-2 infection, all cases preceded COVID-19 outbreaks. No instances of complicated HZ were reported. In multivariate analysis, impaired T helper and T cytotoxic cell counts independently correlated with HZ occurrence. These findings provide the first evidence that cancer patients on active treatment have a not negligible risk of developing HZ within 30 days after the third dose of tozinameran. The favorable clinical outcome of all observed cases confirms that protective effects of boosters in reducing the risk of severe COVID-19 outweigh the potential risk of HZ occurrence.

show abstract

“…In addition, severe adverse events for cardiovascular, renal, and autoimmune diseases and reproductive health issues have been reported regardless of the causality. Accordingly, individuals with pre-existing conditions need to be cautious of COVID-19 vaccination [ 15 ]. The development of autoimmune skin diseases after COVID-19 vaccination, such as the development, worsening, or recurrence of alopecia areata, has been reported.…”

mentioning

confidence: 99%